Revise laws related to state purchase of opioid antagonists

SB 112 would prohibit Montana state funds (including federal funds) from purchasing opioid reversal drugs after June 30, 2025, from companies involved in opioid settlement agreements. It allows existing contracts for these drugs to continue until fulfillment but bans renewal after the deadline, and requires continued supply under settlement agreements signed before September 1, 2024. The bill directly affects state agencies purchasing opioid reversal medications and pharmaceutical companies that settled opioid-related lawsuits. The bill died in committee in May 2025 and did not become law.